
Summit Therapeutics Inc. (SMMT) Stock Ticker
SMMT right now
Market factors today
Unlock the full SMMT picture
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT stock facts
| Ticker symbol | SMMT |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $12.5B |
| CEO | Robert W. Duggan |
| Employees | 265 |
| Headquarters | Miami, FL, US |
| IPO date | 2015-03-05 |
| Website | www.smmttx.com |
What you can see for SMMT on Tickr
Live SMMT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SMMT report.
Rankings
FAQ
What is the ticker symbol for Summit Therapeutics Inc.?
The ticker symbol for Summit Therapeutics Inc. is SMMT, listed on the NASDAQ Global Market.
What is SMMT?
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an…